Cancer has troubled the minds of expert researchers and the most resourceful nations around the world. The most common types breast and prostate cancer kill thousands of Americans every year. According to data analytics, colon cancer is on the rise and proves to be adding to the catastrophe immensely. It is not news that the diagnosis and treatment of the illness in its early stage presents a better opportunity for the patient to kill the cancerous cells and live a normal healthy life.
There are numerous studies around the world delving into the intricacies of cancer cells. Most researchers develop treatments concurrently along therapies. Lately, genetics have come up as factors that could shift the treatments of patients to match up individual sequences. One of the scientists with intense studies on the matter is Clay Siegall, whose career is focused on the issues that trouble governments worldwide.
Clay Siegall stated that cancer researchers are utilizing the full benefits of genetic extraction developed in the recent years. So far, they have established that cancer can be the result of genes and not just diet, environment and other external factors. Using DNA sequencing, practitioners can tailor a treatment plan that suits each patient effectually. He added that a Dutch based research firm has successfully developed a diagnosis and treatment scheme that runs for only two weeks from the time a patient requires accurate diagnosis.
Clay Siegall is the co-founder chief executive officer and president of Seattle Genetics. Clay Siegall has a specialization in cancer treatment using DNA mapping. He started Seattle Genetics to employ high tech detailed research methods that would surpass previous research attempts.
His interests in the field stemmed from the trauma of watching his father die of cancer at the age of 24. His father suffered the illness for five years and passed away due to lack of better diagnosis and treatment. He dedicated his life to giving cancer patients hope for the future and eliminate pain from them and their families. Before starting Seattle, he worked with Bristol-Meyers Squibb Pharmaceutical Research Institute. Currently, he has contracts with Genentech, Pfizer, and GlaxoSmithKline to develop treatments.